PL375536A1 - Zastosowanie antagonistów CGRP do leczenia łuszczycy - Google Patents

Zastosowanie antagonistów CGRP do leczenia łuszczycy

Info

Publication number
PL375536A1
PL375536A1 PL03375536A PL37553603A PL375536A1 PL 375536 A1 PL375536 A1 PL 375536A1 PL 03375536 A PL03375536 A PL 03375536A PL 37553603 A PL37553603 A PL 37553603A PL 375536 A1 PL375536 A1 PL 375536A1
Authority
PL
Poland
Prior art keywords
psoriasis
treatment
antagonist compounds
cgrp antagonist
remedying
Prior art date
Application number
PL03375536A
Other languages
English (en)
Inventor
Birkir Sveinsson
Original Assignee
Birkir Sveinsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birkir Sveinsson filed Critical Birkir Sveinsson
Publication of PL375536A1 publication Critical patent/PL375536A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5753—Calcitonin gene related peptide
PL03375536A 2002-08-12 2003-08-12 Zastosowanie antagonistów CGRP do leczenia łuszczycy PL375536A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IS6496 2002-08-12

Publications (1)

Publication Number Publication Date
PL375536A1 true PL375536A1 (pl) 2005-11-28

Family

ID=36701412

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03375536A PL375536A1 (pl) 2002-08-12 2003-08-12 Zastosowanie antagonistów CGRP do leczenia łuszczycy

Country Status (23)

Country Link
US (5) US20110150890A1 (pl)
EP (1) EP1556020B1 (pl)
JP (1) JP2006501216A (pl)
KR (1) KR101070213B1 (pl)
CN (1) CN1674919A (pl)
AT (1) ATE423553T1 (pl)
AU (1) AU2003260944B2 (pl)
BR (1) BR0313388A (pl)
CA (1) CA2495498C (pl)
DE (1) DE60326370D1 (pl)
DK (1) DK1556020T3 (pl)
EA (1) EA008744B1 (pl)
ES (1) ES2323170T3 (pl)
IL (1) IL166761A (pl)
IS (1) IS2902B (pl)
MX (1) MXPA05001649A (pl)
NO (1) NO20051262L (pl)
NZ (1) NZ538615A (pl)
PL (1) PL375536A1 (pl)
PT (1) PT1556020E (pl)
RS (1) RS52750B (pl)
SI (1) SI1556020T1 (pl)
WO (1) WO2004014351A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0313388A (pt) 2002-08-12 2005-07-05 Birkir Sveinsson Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
ES2664421T3 (es) 2005-11-14 2018-04-19 Teva Pharmaceuticals International Gmbh Anticuerpo antagonista dirigido contra un péptido relacionado con el gen de la calcitonina
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2011024113A1 (en) 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
CN108373502B (zh) 2011-05-20 2022-03-22 H.伦德贝克公司 抗cgrp组合物及其用途
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
KR102098546B1 (ko) 2011-05-20 2020-04-07 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
JP5923375B2 (ja) * 2012-04-24 2016-05-24 花王株式会社 Ｃｇｒｐ応答性促進剤
DK3119431T3 (da) 2014-03-21 2024-03-18 Teva Pharmaceuticals Int Gmbh Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
WO2016116948A1 (en) 2015-01-22 2016-07-28 Ram Isanaka Peptide for treating inflammatory diseases
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
WO2017001433A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
EP3515937A1 (en) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating refractory migraine
US11433119B2 (en) 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders
WO2018236873A1 (en) * 2017-06-19 2018-12-27 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION
WO2019087161A1 (en) * 2017-11-06 2019-05-09 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof
KR20200139720A (ko) 2018-04-02 2020-12-14 암젠 인크 에레누맙 조성물 및 이의 용도
WO2019213660A2 (en) * 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
CN111867559A (zh) * 2019-01-25 2020-10-30 株式会社爱茉莉太平洋 含有苯甲酰胺化合物以及增溶剂的组合物
AR126954A1 (es) * 2021-09-02 2023-12-06 Biohaven Pharm Holding Co Ltd Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7953194A (en) * 1994-08-16 1996-03-07 Human Genome Sciences, Inc. Calcitonin receptor
FR2729855A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
EP0934068A1 (en) * 1996-09-09 1999-08-11 Smithkline Beecham Corporation Compounds and methods
WO1998056779A1 (en) * 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6214816B1 (en) * 1998-03-17 2001-04-10 Novo Nordisk A/S Heterocyclic compounds
ES2137136B1 (es) * 1998-05-18 2000-07-01 Esteve Labor Dr Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica.
WO2000018764A1 (en) 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
CZ20032081A3 (cs) 2001-02-01 2004-01-14 Biogen, Inc. Kombinace inhibitoru interakce CD2/LFA-3 a UVB záření pro použití při léčení kožních onemocnění
BR0313388A (pt) 2002-08-12 2005-07-05 Birkir Sveinsson Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
WO2009033809A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP3490581A4 (en) 2016-07-26 2020-10-14 Flagship Pioneering Innovations V, Inc. NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR TREATMENT OF CANCER

Also Published As

Publication number Publication date
IL166761A0 (en) 2006-01-15
WO2004014351A3 (en) 2004-06-17
MXPA05001649A (es) 2005-05-27
DE60326370D1 (de) 2009-04-09
AU2003260944B2 (en) 2009-05-14
ES2323170T3 (es) 2009-07-08
US20230181693A1 (en) 2023-06-15
KR101070213B1 (ko) 2011-10-06
CA2495498A1 (en) 2004-02-19
RS52750B (sr) 2013-08-30
WO2004014351A2 (en) 2004-02-19
US9585940B2 (en) 2017-03-07
DK1556020T3 (da) 2009-06-22
ATE423553T1 (de) 2009-03-15
BR0313388A (pt) 2005-07-05
US10668132B2 (en) 2020-06-02
EP1556020B1 (en) 2009-02-25
JP2006501216A (ja) 2006-01-12
CA2495498C (en) 2014-04-15
NO20051262L (no) 2005-03-11
EA200500306A1 (ru) 2005-08-25
CN1674919A (zh) 2005-09-28
KR20050056198A (ko) 2005-06-14
EA008744B1 (ru) 2007-08-31
US20170065681A1 (en) 2017-03-09
US20110150890A1 (en) 2011-06-23
AU2003260944A1 (en) 2004-02-25
EP1556020A2 (en) 2005-07-27
US20200338168A1 (en) 2020-10-29
IS7741A (is) 2005-03-14
PT1556020E (pt) 2009-05-29
US20140220030A1 (en) 2014-08-07
IS2902B (is) 2014-10-15
SI1556020T1 (sl) 2009-08-31
IL166761A (en) 2010-12-30
US11266718B2 (en) 2022-03-08
NZ538615A (en) 2008-03-28
RS20050132A (en) 2007-11-15

Similar Documents

Publication Publication Date Title
IL166761A0 (en) Use of CGRP antagonist compounds for treatment of psoriasis
EP1429729A4 (en) MIXED DOSAGE FORM COMPRISING A HYPOCHOLESTEROLEMIANT, A RENIN-ANGIOTENSIN INHIBITOR, AND ASPIRIN
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
ATE277596T1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
CY2439B1 (en) Alpha-TNF antagonists in a cosmetic, pharmaceutical or dermotological composition.
IL178745A0 (en) Methods for treatment and management of scleroderma using 4-(amino)-2(2,6-dioxo(3-piperidyl))-isoindoline -1,3-dione
AU2003301190A8 (en) Administration of capsaicinoids
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
DK0714304T3 (da) Terapeutisk system til behandling af psoriasis
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
WO2003103675A3 (en) COMBINATION THERAPIES FOR PURINOCEPTOR RELATED DISORDERS
WO2005009388A3 (en) Antiglucocorticoids for the treatment of catatonia
Lavrova et al. Modern pharmacotherapy of onychomycosis
WO2007002174A3 (en) A method of treatment of hormone depletion induced vasomotor symptoms
UA36361A (uk) Спосіб лікування захворювань щитовидної залози
BR0013552A (pt) Azatioprina tópica para o tratamento de doenças auto-imunes orais

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)